
HeartBeam (BEAT) Stock Forecast & Price Target
HeartBeam (BEAT) Analyst Ratings
Bulls say
HeartBeam Inc. is positioned favorably within the burgeoning mobile ECG devices market, which is projected to expand from a valuation of $4.1 billion in 2024 to $8.9 billion by 2032, driven by increasing incidences of cardiac disease and the demand for remote diagnosis solutions. The company’s proprietary Vector Electrocardiography (VECG) technology platform has demonstrated high sensitivity (92-100%) and improved specificity (54-58%), which enhances the potential for FDA clearance and market adoption. Furthermore, with a target market of 2.6 million elevated-risk patients and potential annual revenue ranging from $1.3 billion to $2.6 billion, HeartBeam's growth prospects are bolstered by an anticipated shift towards reimbursement-driven revenue models and the expansion of patient subscription services.
Bears say
HeartBeam Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from potential reimbursement issues that could limit product demand and adversely affect revenue. The company’s product performance metrics indicate limitations in accuracy, particularly highlighted by its lower area under curve (AUC) values in “spot” mode, which could undermine its competitive edge in cardiac monitoring. Additionally, the auditors’ going-concern opinion raises substantial doubts regarding the company’s financial viability without new funding, suggesting that ongoing negative cash flows may persist into 2025 and 2026, further complicating its operational stability and investor confidence.
This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.
HeartBeam (BEAT) Analyst Forecast & Price Prediction
Start investing in HeartBeam (BEAT)
Order type
Buy in
Order amount
Est. shares
0 shares